Shreya Agarwal: We Describe Patients With PLG Mutations Who Experienced Recurrent TMA
Shreya Agarwal, Assistant Professor of Pediatric Hematology at UCSF Benioff Children’s Hospitals, reposted from RPTH Journal on LinkedIn:
”Grateful to RPTH for highlighting our recent study on Plasminogen (PLG) mutation- associated thrombotic microangiopathy (TMA).
In this work, we describe patients with PLG mutations who experienced recurrent TMA despite complement blockade therapy, and raises suspicion if there is an alternate disease pathway worth exploring.
We are now hoping to assess the feasibility of a multicenter study to better understand PLG mutations-associated TMA.
If you’ve cared for patients with plasminogen mutations and TMA, we’d be grateful if you could take a few minutes to complete our short survey.
Thank you to my amazing coauthors Nicola Pozzi, Senthil Sukumar, Camila Masias MD, Anuja Java and Spero Cataland for their collaboration on this project!”
Quoting RPTH Journal‘s post:
”Not all thrombotic microangiopathies (TMAs) behave the same, and they don’t all respond to complement blockade.
In a new study, Shreya Agarwal, MD and team describe a subset of patients with plasminogen (PLG) mutations who experienced recurrent TMA despite standard therapy.
Their response to anticoagulation hints at an alternative disease pathway worth exploring.
Coauthors: Nicola Pozzi; Senthil Sukumar, Camila Masias MD, Spero Cataland’‘
Read the full article in RPTH.
Article: Plasminogen mutation–associated thrombotic microangiopathy and role of anticoagulation: a single institution case series
Authors: Shreya Agarwal, Nicola Pozzi, Senthil Sukumar, Camila Masias, Anuja Java, Spero Cataland

Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.
-
Jun 15, 2026, 10:49Aurelio Maggio: How Is The Treatment Landscape Of Thrombotic Thrombocytopenic Purpura Evolving?
-
Jun 15, 2026, 10:49Marek Mráz: A Landmark EHA 2026 for Our Lab
-
Jun 15, 2026, 10:32Magnus Ek: Operational Excellence in Delivering Seamless Access for 17,000 Delegates at EHA 2026 Congress
-
Jun 15, 2026, 10:15Carol Bewick: Why the Global Community Makes EHA 2026 Unforgettable
-
Jun 15, 2026, 10:07Habib Bennaceur: Driving Haemoglobinopathies Progress Across Multiple Clinical Programmes At EHA 2026
-
Jun 14, 2026, 22:49Cihan Ay: From First Oral Presentation to Pro and Con Debate – A 20-Year EHA Journey
-
Jun 14, 2026, 19:54Tareq Abadl: What Happens If You Transfuse the Wrong Blood Group?
-
Jun 14, 2026, 19:46Amber Yates: Stretching Scientific Muscles in Areas of Hematology – Day 2 at EHA 2026
-
Jun 14, 2026, 19:41Peter Loffelhardt: Thousands of People Coming in – Second Day at EHA 2026